Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.

What Was Tested

Researchers studied DMSO (dimethyl sulfoxide, non-peptide solvent) in this clinical trial publication.

50 patients receiving ASCT in the outpatient setting.

Subjectivity of nausea, potential Hawthorne Effect.

Who Took Part

According to the abstract, 50 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Comprehensive cancer center outpatient infusion department.

Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells.

How the Study Was Run

Nonrandomized cohort using historical control.

A standard script was used to ensure consistency.

Number and volume of stem cells bags, as well as infusion rate and emesis episodes, were recorded.

Nausea scores and vomiting episodes were compared to historical data.

What Was Measured

Topics PubMed links to this paper include Antiemetics, Blood Transfusion, Autologous, Cohort Studies, Cryoprotective Agents, Dimethyl Sulfoxide, Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation.

What This Means in Plain Language

This is a clinical trial of DMSO (dimethyl sulfoxide, non-peptide solvent) in 50 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Oncology nursing forum), a journal based in United States.

More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.